Nkarta, Inc.

NKTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.66

+$0.19 · +7.69%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

44/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Paul J. Hastings
Listed since: Jul 10, 2020
Employees: 106

Market position

Day range

Current $2.66

$2.48$2.735

52-week range

Current $2.66

$1.70$3.72

Open: $2.48
Previous close: $2.47
Volume: 1.06M; 1.38× average
Average volume: 769.11K; Average daily volume
Market cap: 190.31M USD
Beta: 0.94; Market reference 1
50-day average: $2.6198; +1.53% above average
200-day average: $2.3972; +10.97% above average

Financials

Financial statements

Income trends

Operating income

−121.21M USD+5.45%

Net income

−104.08M USD+4.33%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	9.19M USD	—	5.87M USD	—	—
Gross profit	−9.19M USD	—	−5.87M USD	—	—
Research and development	90.43M USD	96.74M USD	90.9M USD	90.9M USD	63.41M USD
Selling, general, and administrative	31.57M USD	31.45M USD	34.88M USD	28.06M USD	23.02M USD
Operating expenses	112.01M USD	128.19M USD	125.78M USD	118.96M USD	86.43M USD
Interest income	15.49M USD	19.32M USD	14.11M USD	5.59M USD	370K USD
Interest expense	—	—	—	5.59M USD	—
Depreciation and amortization	9.19M USD	9.15M USD	5.87M USD	2.64M USD	1.76M USD
Operating income	−121.21M USD	−128.19M USD	−131.65M USD	−118.96M USD	−86.43M USD
Net income	−104.08M USD	−108.79M USD	−117.5M USD	−113.84M USD	−86.08M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$9.00

238.35% upside

Past 12 months12-month forecastHigh $9.00Average $9.00Low $9.00

NKTX news

globenewswire.comJul 23, 2026

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector…

Read source

globenewswire.comJun 26, 2026

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.

Read source

prnewswire.comMay 29, 2026

The $13 Million Company Teaching the Immune System to Hunt Cancer

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)

Read source